Many Australians living with neurological disorders, such as motor neurone disease and multiple sclerosis, experience speech difficulties and may lose their ability to speak.
Multiple sclerosis (MS) can have a substantial impact on many aspects of life beyond physical health, with 51% of people reporting that the disease affects their social life and 48% reporting that it affects their work, according to new research presented at the European Academy of Neurology (EAN) Congress 2026.
Dysphagia, a severe comorbidity of many neurological diseases, often lacks targeted therapies. This critical review assessed the clinical effectiveness and safety of electrical stimulation of cranial nerves for treating dysphagia, including implantable (direct nerve stimulation), minimally invasive (pharyngeal electrical stimulation, PES), and non‑invasive (transcutaneous) approaches.
Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
